Theraclion, the only medtech company in the world developing an innovative technology for the treatment of hyperparathyroidism1, today announced that it has been granted €8.5 million in R&D funding by OSEO (the French state innovation agency) as part of the TUCE strategic industrial innovation project on elastography-guided ultrasound therapy.

read more